Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05363618 · ClinicalTrials.gov registry record · NA
Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn
A NA study, sponsored by Microbiome Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 211
- Enrollment target
NCT05363618 is a NA study that has completed, run by Microbiome Health Sciences. The registered enrollment target is 211 participants.
The verdict
NCT05363618, a NA study, has completed, sponsored by Microbiome Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 211 participants
- Enrollment target
Study Summary
Remote un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in subjects with heartburn. Candidates will have heartburn and be taking daily PPIs at up to twice the standard OTC or prescription dosage. Approximately 400 subjects (men and women of all races and ethnicities) will be randomly enrolled in a 1:1 ratio to receive Product or Placebo (1.4 ml) per day.
Interventions
- DIETARY_SUPPLEMENT Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
- OTHER Placebo 1.4 ml
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-05-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05363618
The ClinicalTrials.gov registry entry for NCT05363618 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Microbiome Health Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml) is the first listed.
NCT05363618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05363618 about?
NCT05363618 is a clinical study titled "Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn". Remote un-controlled trial to evaluate the tolerability of MHS-1031 and separately the tolerability of the formulated placebo in subjects with heartburn. Candidates will have heartburn and be taking daily PPIs at up to twice the standard OTC or prescription dosage. Approximately 400 subjects (men an...
What is the current status of trial NCT05363618?
This trial is currently completed. It is a NA study. The enrollment target is 211 participants. The study started on 2022-02-10. Estimated completion is 2023-05-30.
What interventions are being tested in trial NCT05363618?
The interventions under investigation include: Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml) (DIETARY_SUPPLEMENT), Placebo 1.4 ml (OTHER).
Who is sponsoring clinical trial NCT05363618?
This trial is sponsored by Microbiome Health Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.